AngioDynamics (ANGO) to Release Earnings on Tuesday

AngioDynamics (NASDAQ:ANGO) is expected to be posting its Q2 2026 results before the market opens on Tuesday, January 6th. Analysts expect AngioDynamics to post earnings of ($0.10) per share and revenue of $76.4330 million for the quarter. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, January 6, 2026 at 8:00 AM ET.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. The firm had revenue of $75.71 million during the quarter, compared to analyst estimates of $72.69 million. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.AngioDynamics’s revenue was up 12.1% compared to the same quarter last year. During the same period last year, the business posted ($0.11) earnings per share. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AngioDynamics Price Performance

ANGO stock opened at $12.87 on Tuesday. The business’s 50-day moving average is $12.61 and its two-hundred day moving average is $10.91. The firm has a market capitalization of $530.24 million, a P/E ratio of -16.50 and a beta of 0.49. AngioDynamics has a 1 year low of $8.27 and a 1 year high of $13.99.

Insider Activity

In other news, CEO James C. Clemmer purchased 10,000 shares of the business’s stock in a transaction on Thursday, October 9th. The shares were bought at an average price of $11.15 per share, with a total value of $111,500.00. Following the completion of the transaction, the chief executive officer directly owned 882,529 shares in the company, valued at approximately $9,840,198.35. This represents a 1.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Lawrence T. Weiss bought 10,000 shares of the stock in a transaction dated Tuesday, October 21st. The shares were acquired at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the completion of the transaction, the senior vice president owned 93,597 shares of the company’s stock, valued at approximately $1,105,380.57. The trade was a 11.96% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 20,890 shares of company stock worth $239,532. Corporate insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

A number of institutional investors and hedge funds have recently made changes to their positions in ANGO. State of Wyoming purchased a new stake in shares of AngioDynamics in the second quarter valued at approximately $31,000. Russell Investments Group Ltd. boosted its position in shares of AngioDynamics by 329.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 3,213 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of AngioDynamics by 359.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 4,268 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of AngioDynamics by 106.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,473 shares of the medical instruments supplier’s stock valued at $83,000 after purchasing an additional 3,846 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of AngioDynamics in the 2nd quarter valued at about $90,000. 89.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Canaccord Genuity Group increased their target price on AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a report on Friday, October 3rd. Finally, Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.